WRN and cancer: Although WRN was categorised as a drug target group II candidate by the Open Target Platform [36] (Methods), there are currently several drug development programs underway to target WRN [123, 124] in MSI cancer; therefore, we re-classified it as a drug target group I and priority class A gene.